- Home
- XOS vs BNR Comparison
XOS vs BNR Comparison
Compare XOS & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOS
- BNR
- Stock Information
- Founded
- XOS 2016
- BNR 2014
- Country
- XOS United States
- BNR China
- Employees
- XOS N/A
- BNR N/A
- Industry
- XOS Construction/Ag Equipment/Trucks
- BNR Medical Specialities
- Sector
- XOS Consumer Discretionary
- BNR Health Care
- Exchange
- XOS Nasdaq
- BNR Nasdaq
- Market Cap
- XOS 27.8M
- BNR 29.1M
- IPO Year
- XOS N/A
- BNR 2020
- Fundamental
- Price
- XOS $3.79
- BNR $2.40
- Analyst Decision
- XOS Buy
- BNR
- Analyst Count
- XOS 5
- BNR 0
- Target Price
- XOS $10.00
- BNR N/A
- AVG Volume (30 Days)
- XOS 20.2K
- BNR 50.4K
- Earning Date
- XOS 05-19-2025
- BNR 05-28-2025
- Dividend Yield
- XOS N/A
- BNR N/A
- EPS Growth
- XOS N/A
- BNR N/A
- EPS
- XOS N/A
- BNR N/A
- Revenue
- XOS $55,961,000.00
- BNR $70,669,261.00
- Revenue This Year
- XOS $3.96
- BNR $136.32
- Revenue Next Year
- XOS $37.96
- BNR N/A
- P/E Ratio
- XOS N/A
- BNR N/A
- Revenue Growth
- XOS 25.69
- BNR N/A
- 52 Week Low
- XOS $2.73
- BNR $2.18
- 52 Week High
- XOS $9.22
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- XOS 52.11
- BNR 23.70
- Support Level
- XOS $3.70
- BNR $2.30
- Resistance Level
- XOS $3.98
- BNR $2.78
- Average True Range (ATR)
- XOS 0.22
- BNR 0.28
- MACD
- XOS 0.00
- BNR 0.04
- Stochastic Oscillator
- XOS 54.34
- BNR 16.53
About XOS Xos Inc.
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.